Sold as Etopophos Preservative Free. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Etoposide Phosphate (sold as Etopophos Preservative Free), first approved May 17, 1996, with 0 new uses approved and 0 published complete response letters.
| Etopophos | Part B | $499K | -15% | 3,252 |
| Etopophos | Part D | $0K | -100% | 0 |
| Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung CancerSCLC, Extensive Stage · LI FENG | Not applicable | Not yet recruiting | Nov 10, 2026 |
| Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute LeukemiaAcute Leukemia, High Risk, Acute Leukemia Refractory · Guangdong Second Provincial General Hospital | Phase 2 | Enrolling by invitation | Nov 6, 2026 |
| Allogeneic Cell Therapy in Refractory T-Cell LymphomaLymphoma, T Cell, Peripheral · University Medical Center Goettingen | Phase 2 | Not yet recruiting | Nov 5, 2026 |
| A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung CancerLimited Stage Small-Cell Lung Cancer · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 / Phase 3 | Not yet recruiting | Nov 5, 2026 |
| Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaInfant-Type Hemispheric Glioma · St. Jude Children's Research Hospital | Phase 2 | Not yet recruiting | Nov 4, 2026 |
| Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer (SCLC), SCLC, Extensive Stage · Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Nov 2, 2026 |
| Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerLung Cancer, Mesothelioma · Oliver Jonas | Early phase 1 | Not yet recruiting | Oct 23, 2026 |
| Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung CancerSmall Cell Lung Cancer (SCLC) · Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Oct 21, 2026 |
| May 17, 1996 | Etopophos Preservative FreeNDA 20457 · New active ingredient | Cheplapharm | 11 | Marketed |
| Feb 27, 1998 | Etopophos Preservative FreeNDA 20906 · New dosage form | Bristol Myers Squibb | 2 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bristol Myers Squibb